Risk factor
Strong & resilient to price shocks
Profitability factor
Greatly overvalued vs peers
About
Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical API, chemical medicines, proprietary Chinese medicines, and nuclide drugs products in China. It offers heparin, chondroitin sulphate, and glucosamine series products, as well as collagen, hyaluronic acid, and cytochrome C for use in the therapeutic areas of cardiovascular,...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA
Target Price
The average target price of 002675.SZ is 18 and suggests 36% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell